People with mild cognitive impairment can now begin Leqembi at home with injection training, while eligibility and brain-scan safety checks remain unchanged. The change is a once-weekly under-the-skin starting dose; what stayed the same is who qualifies and how closely doctors monitor risk. Leqembi Iqlik (lecanemab-irmb) is a prescription medicine for early Alzheimer's disease, a stage that includes mild cognitive impairment and mild dementia from Alzheimer's. Eisai and Biogen said in the FDA approval announcement that eligible patients received FDA approval on July 13, 2026 to start treatment at home without completing 18 months of IV infusions first.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Starting treatment at home
- What the weekly dose looks like
- What injection training includes
- What did not change for safety
Starting treatment at home
Patients no longer must start with IV infusions in a clinic. They may stay on IV or under-the-skin dosing for the whole course.
They may also switch between IV and under-the-skin dosing when their care team advises it. That flexibility matters for travel, work schedules, caregiver help, and infusion access. The decision still starts with a memory clinic visit, diagnosis confirmation, and safety screening.
What the weekly dose looks like
The initiation regimen is 500 mg once weekly, given as two consecutive 250-mg autoinjector injections of about 15 seconds each. After 18 months of IV or under-the-skin treatment, the dose lowers to 360 mg weekly for maintenance.
Two injections means planning a quiet time, a clean surface, and help nearby for the first doses. A care partner can learn the same steps and observe for problems.
What injection training includes
Training focuses on device use, dose tracking, and when to call the care team. Eisai and Biogen describe support in the launch update as device education through the specialty-pharmacy network plus take-home tools.
Practice with the Demo Kit before handling the real dose. Use the tracker or app at injection time, not from memory later.
- Instructions-for-Use video for step-by-step autoinjector handling
- Iqlik Welcome Kit with Demo Kit for practice and treatment tracker for doses
- Leqembi Companion app for reminders and treatment records
- Specialty-pharmacy education for questions about technique and missed doses
What did not change for safety
The indication remains adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. Home dosing did not widen eligibility to later dementia stages or to memory problems without confirmed Alzheimer's cause. Brain MRI is still required before starting treatment and at specified points afterward, exactly as with IV dosing. NeurologyLive reports in its approval summary that the boxed ARIA warning, ApoE ε4 genotyping discussion, and anticoagulant-related bleeding caution remain central to selection and counseling.
ARIA means brain swelling or bleeding that needs prompt imaging and medical review. Approval rested on Clarity AD extension substudies showing equivalent drug exposure and comparable ARIA-E rates, not a new large efficacy trial. Initiation-dose supply launched through U.S. specialty pharmacies in late August 2026. Bring the treatment tracker and MRI schedule to every follow-up visit.
You Might Also Like
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: What Changed and What Did Not for People With Mild Cognitive Impairment
- MRI and ARIA Monitoring With At-Home Leqembi in 2026: What Changed and What Did Not for People With Mild Cognitive Impairment
- PrecivityAD2 Testing for Symptomatic Adults 40 and Older in 2026: What Is Established and What Remains Uncertain for People With Mild Cognitive Impairment





